Shariff Erum, Shahid Rizwana
Department of Neurology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Turk J Emerg Med. 2025 Jul 1;25(3):246-249. doi: 10.4103/tjem.tjem_220_24. eCollection 2025 Jul-Sep.
Capsular warning syndrome (CWS) is a rare condition marked by recurrent, stereotypical transient ischemic attacks (TIAs) affecting the face, arm, and leg, without cortical involvement. It is associated with a high risk of a full-blown stroke within 7 days. The exact pathophysiological mechanism and optimal management strategies remain debated. It is crucial to distinguish CWS from crescendo TIAs and consider reperfusion therapy if new episodes occur within the therapeutic window for systemic reperfusion, in order to prevent a disabling stroke. We present the case of a 53-year-old male who arrived at the emergency department (ED) with right hemiparesis and facial weakness lasting for 1 h. He had experienced four recurrent, stereotypical episodes over the past 7 h and was diagnosed with a TIA, despite being within the therapeutic window for thrombolysis. He was started on dual antiplatelet therapy, high-dose statins, and management of other vascular risk factors. However, within 24 h, his condition progressed to a complete stroke with severe hemiparesis and facial weakness. Magnetic resonance imaging confirmed infarction in the left hemisphere, while a computed tomography angiogram was normal. This case underscores the importance of prompt recognition of CWS in the ED, enabling activation of stroke services and the consideration of reperfusion therapy when appropriate, to minimize the risk of a disabling stroke.
囊状预警综合征(CWS)是一种罕见病症,其特征为反复出现的刻板性短暂性脑缺血发作(TIA),累及面部、手臂和腿部,不累及皮质。它与7天内发生全面性卒中的高风险相关。确切的病理生理机制和最佳管理策略仍存在争议。将CWS与渐强性TIA区分开来并在全身再灌注治疗窗内出现新发作时考虑再灌注治疗至关重要,以预防致残性卒中。我们报告一例53岁男性病例,他因右侧偏瘫和面部无力持续1小时而抵达急诊科(ED)。在过去7小时内,他经历了四次反复出现的刻板发作,尽管处于溶栓治疗窗内,但仍被诊断为TIA。他开始接受双联抗血小板治疗、高剂量他汀类药物治疗以及其他血管危险因素的管理。然而,在24小时内,他的病情进展为完全性卒中,伴有严重偏瘫和面部无力。磁共振成像证实左半球梗死,而计算机断层血管造影正常。该病例强调了在急诊科及时识别CWS的重要性,以便启动卒中服务并在适当的时候考虑再灌注治疗,以将致残性卒中的风险降至最低。